Idursulfase: a poor risk-benefit balance in type II mucopolysaccharidosis.
Weekly infusions of idursulfase have no tangible benefit in boys with type II mucopolysaccharidosis who already have respiratory involvement, while hypersensitivity reactions are frequent and sometimes serious. Idursulfase should only be given to infants if they are enrolled in clinical trials.
D002648:Child; D002986:Clinical Trials as Topic; D017277:Drug Approval; D005060:Europe; D006801:Humans; D007066:Iduronate Sulfatase / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D016532:Mucopolysaccharidosis II / Q000188:drug therapy*
D007066:Iduronate Sulfatase